Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Alvotech Warrant (ALVOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ALVOW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 28.92% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 3873 | Beta 0.19 | 52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 |
52 Weeks Range 1.02 - 4.99 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.42% | Operating Margin (TTM) 7.97% |
Management Effectiveness
Return on Assets (TTM) 7.02% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 100126591 |
Shares Outstanding - | Shares Floating 100126591 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alvotech Warrant
Company Overview
History and Background
Alvotech, founded in 2012, is a global biopharmaceutical company focused on the development and manufacture of biosimilar medicines. It merged with Oaktree Acquisition Corp. II, a special purpose acquisition company (SPAC), to become publicly listed. The warrant (ALVTW) gives the holder the right to purchase shares of Alvotech at a specific price and within a specific timeframe.
Core Business Areas
- Biosimilar Development and Manufacturing: Alvotech focuses on developing and manufacturing biosimilars, which are follow-on versions of biologic drugs.
Leadership and Structure
Robert Wessman serves as the Chairman and CEO. The company has a board of directors with experience in biopharmaceuticals and finance. Organisational structure involves research & development, manufacturing, commercial operations and corporate functions.
Top Products and Market Share
Key Offerings
- AVT02 (Biosimilar Humira): Alvotechu2019s lead product is a biosimilar of Humira (adalimumab), a blockbuster drug used to treat autoimmune diseases. Launching biosimilars involves navigating complex patent landscapes and regulatory approvals. Market share data varies by region and launch date. Competitors include Amgen (AMGN), Sandoz (SDZNY), Coherus BioSciences (CHRS), and Viatris (VTRS).
Market Dynamics
Industry Overview
The biosimilars market is growing rapidly, driven by increasing healthcare costs and patent expirations of original biologic drugs. This market is subject to evolving regulatory frameworks and competitive pressures.
Positioning
Alvotech positions itself as a leader in the biosimilars space, focusing on high-value targets. Its competitive advantages include its advanced manufacturing capabilities and global partnerships.
Total Addressable Market (TAM)
The global biosimilars market is expected to reach hundreds of billions of dollars. Alvotech aims to capture a significant share of this market through its pipeline of biosimilar products. The TAM could be $100-$200 billion by 2030.
Upturn SWOT Analysis
Strengths
- Strong pipeline of biosimilar candidates
- Advanced manufacturing capabilities
- Experienced management team
- Global partnerships
Weaknesses
- Dependence on regulatory approvals
- Intense competition in the biosimilars market
- Potential for patent litigation
- Financial losses and reliance on funding
Opportunities
- Expanding biosimilars market
- New product launches
- Strategic partnerships and acquisitions
- Increasing acceptance of biosimilars by healthcare providers and patients
Threats
- Regulatory hurdles
- Price competition
- Intellectual property challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- AMGN
- VTRS
- CHRS
- SDZNY
Competitive Landscape
Alvotech faces intense competition from established pharmaceutical companies in the biosimilars market. Its success depends on its ability to differentiate its products and secure regulatory approvals.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent emergence as a publicly traded entity.
Future Projections: Future growth is dependent on the successful launch and commercialization of its biosimilar products.
Recent Initiatives: Recent initiatives include regulatory submissions for its biosimilar candidates and partnerships with pharmaceutical companies to commercialize its products.
Summary
Alvotech is a developing biopharmaceutical company in the biosimilars space that has good potential. They are in early stages of revenue generation and subject to regulatory approvals and competitive market pressures. Its success depends on effectively commercializing its biosimilar pipeline and handling the competitive landscape. Alvotech's financial performance has to be observed carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.